GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nymox Pharmaceutical Corp (OTCPK:NYMXF) » Definitions » Net Debt Paydown Yield %

NYMXF (Nymox Pharmaceutical) Net Debt Paydown Yield % : 0% (As of May. 12, 2025)


View and export this data going back to 1997. Start your Free Trial

What is Nymox Pharmaceutical Net Debt Paydown Yield %?

Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt. As of today, Nymox Pharmaceutical's Net Debt Paydown Yield % was 0%.


Nymox Pharmaceutical Net Debt Paydown Yield % Historical Data

The historical data trend for Nymox Pharmaceutical's Net Debt Paydown Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nymox Pharmaceutical Net Debt Paydown Yield % Chart

Nymox Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Debt Paydown Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.01 -0.14 0.43 -0.10

Nymox Pharmaceutical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Sep24
Net Debt Paydown Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.56 0.20 0.07 -0.10 -

Competitive Comparison of Nymox Pharmaceutical's Net Debt Paydown Yield %

For the Biotechnology subindustry, Nymox Pharmaceutical's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nymox Pharmaceutical's Net Debt Paydown Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nymox Pharmaceutical's Net Debt Paydown Yield % distribution charts can be found below:

* The bar in red indicates where Nymox Pharmaceutical's Net Debt Paydown Yield % falls into.


;
;

Nymox Pharmaceutical Net Debt Paydown Yield % Calculation

Nymox Pharmaceutical's Net Debt Paydown Yield % for the quarter that ended in Sep. 2024 is calculated as:

Net Debt Paydown Yield %
=( TTM Average Debt   (1-Year Ago))-TTM Average Debt )/Market Cap
=( - )/11.2248
=2.46 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.


Nymox Pharmaceutical  (OTCPK:NYMXF) Net Debt Paydown Yield % Explanation

Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.

In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.

We calculating the TTM average debt by adding up the total debt, calculated by the sum of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation, in the trailing twelve months(TTM) divided by the counts of the total debt, accoring to the company's report frequency.


Nymox Pharmaceutical Net Debt Paydown Yield % Related Terms

Thank you for viewing the detailed overview of Nymox Pharmaceutical's Net Debt Paydown Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Nymox Pharmaceutical Business Description

Traded in Other Exchanges
N/A
Address
Bay & Deveaux Streets, Nassau, BHS
Nymox Pharmaceutical Corp is a biopharmaceutical company focused on developing its drug candidate, NX-1207, for the treatment of BPH and the treatment of low-grade localized prostate cancer. It markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. It operates in a single segment, which is research and development of products for the aging population. The company's geographical segments include Canada, United States, and Europe.
Executives
James George Robinson director 10 EAST LEE STREET, SUITE 2705, BALTIMORE MD 21202
Erik Danielsen officer: Chief Financial Officer 9900 CAVENDISH BLVD, ST LAURENT A8 H4M 2V2
Paul Averback director, 10 percent owner, officer: CEO C/O NYMOX PHARMACEUTICAL CORPORATION, 9900 CAVENDISH BLVD., SUITE 306, ST. LAURENT A8 H4M 2V2
Randall J Lanham director, officer: General Counsel

Nymox Pharmaceutical Headlines

From GuruFocus

NYMOX Receives RTF letter from FDA

By PurpleRose PurpleRose 07-12-2022

May 2023 Market Cap Requirement Update

By Value_Insider Value_Insider 11-25-2022

NYMOX Receives RTF letter from FDA

By GuruFocusNews GuruFocusNews 07-02-2022

Nymox Provides Current Update

By sperokesalga sperokesalga 05-10-2023

NYMOX Presenting at Torrey Hills Capital Emerging Growth Conference

By GuruFocusNews GuruFocusNews 11-15-2021

NYMOX Update

By Marketwired 07-07-2023

Nymox Announces Closing of $6.4 Million Financing

By GuruFocusNews GuruFocusNews 04-04-2022